Our Mission, Vision & Values

We develop and manufacture quality products, creating value that exceeds expectations. At our core we solve complex therapeutic challenges together with our partners.

Making a difference in patients’ lives by advancing manufacturing science and therapeutic innovations.

BIOVECTRA’s corporate values shape our decision making and are reflected in our everyday interactions with clients and fellow team members. They outline the experience that customers have come to appreciate and expect.

3 people shapes in blue, purple and gold


Working together
to achieve
a common goal

2 shaking hands, one yellow and the other purple


Recognition and appreciation for the value and values that each BIOVECTRA team member brings

a purple badge with a gold star


Offering products and services of exceptional and unsurpassed caliber, on time and
on budget

a person with long hair, purple sweater and gold checkmark in the corner


Demonstrate expertise and knowledge, holding ourselves accountable to the highest standard

3 hearts in blue, purple and gold


Displaying care and concern for others in
our everyday work

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors